BIOMIRAGEN Trademark

Trademark Overview

On Monday, November 13, 2023, a trademark application was filed for BIOMIRAGEN with the United States Patent and Trademark Office. The USPTO has given the BIOMIRAGEN trademark a serial number of 98266624. The federal status of this trademark filing is REVIVED - AWAITING FURTHER ACTION as of Thursday, October 30, 2025. This trademark is owned by Arcara JHC LLC. The BIOMIRAGEN trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Pharmaceutical products development; Pharmaceutical research services; Testing of pharmaceuticals
biomiragen

General Information

Serial Number98266624
Word MarkBIOMIRAGEN
Filing DateMonday, November 13, 2023
Status616 - REVIVED - AWAITING FURTHER ACTION
Status DateThursday, October 30, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesPharmaceutical products development; Pharmaceutical research services; Testing of pharmaceuticals

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, November 13, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameArcara JHC LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressUwchland, PA 19425

Trademark Events

Event DateEvent Description
Monday, November 13, 2023NEW APPLICATION ENTERED
Tuesday, January 30, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, December 18, 2023TEAS VOLUNTARY AMENDMENT RECEIVED
Friday, May 10, 2024ASSIGNED TO LIE
Friday, May 10, 2024PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Wednesday, June 19, 2024ASSIGNED TO EXAMINER
Sunday, June 23, 2024NON-FINAL ACTION WRITTEN
Sunday, June 23, 2024NON-FINAL ACTION E-MAILED
Sunday, June 23, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, October 7, 2024ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Monday, October 7, 2024ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Saturday, November 9, 2024TEAS PETITION TO REVIVE RECEIVED
Saturday, November 9, 2024PETITION TO REVIVE-GRANTED
Saturday, November 9, 2024NOTICE OF REVIVAL - E-MAILED
Saturday, November 9, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Saturday, November 9, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Saturday, November 9, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, April 8, 2025FINAL REFUSAL WRITTEN
Tuesday, April 8, 2025FINAL REFUSAL E-MAILED
Tuesday, April 8, 2025NOTIFICATION OF FINAL REFUSAL EMAILED
Wednesday, July 23, 2025ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Wednesday, July 23, 2025ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Thursday, September 18, 2025TEAS PETITION TO REVIVE RECEIVED
Friday, October 24, 2025ASSIGNED TO PETITION STAFF
Thursday, October 30, 2025PETITION GRANTED - RESPONSE RECEIVED
Thursday, October 30, 2025NOTICE OF REVIVAL - E-MAILED
Thursday, October 30, 2025ASSIGNED TO LIE
Friday, October 31, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, October 31, 2025TEAS/EMAIL CORRESPONDENCE ENTERED

Related Keywords

biomiragen pharmaceutical testing pharmaceuticals services research products development